This cross-sectional study is the first population-based study, to our knowledge, to describe G-CSF use in 2 nationally representative databases and the first regimen- and patient-level analysis reporting the uptake of both filgrastim and pegfilgrastim biosimilars among patients with cancer receiving myelosuppressive chemotherapy stratified by risk of FN. Here, CSF3 is linked to cancer.